EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen

Hidenori Moriyama iD, Toshifumi Yokota iD

Genes · 2024

DOI: 10.3390/genes15101342 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2024. Verfasst von Hidenori Moriyama und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Superoxide Dismutase-1, Oligonucleotides, Antisense, Mutation. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Friends of Garrett Cumming Research Fund, Muscular Dystrophy Canada, Canadian Institute of Health Research (CIHR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic lateral sclerosis (ALS) is a refractory neurodegenerative disease characterized by the degeneration and loss of motor neurons, typically resulting in death within five years of onset. There have been few effective treatments, making the development of robust therapies an urgent challenge. Genetic mutations have been identified as contributors to ALS, with mutations in superoxide dismutase 1 (SOD1), which neutralizes the harmful reactive oxygen species superoxide, accounting for approximately 2% of all ALS cases. To counteract the toxic gain of function caused by SOD1 mutations, therapeutic strategies aimed at suppressing SOD1 gene expression have shown promise. Antisense oligonucleotide (ASO) is an artificially synthesized, short, single-stranded DNA/RNA molecule that binds to target RNA to alter gene expression, representing a next-generation therapeutic approach. In 2023, tofersen became the first ASO drug approved by the FDA for ALS. Administered intrathecally, tofersen specifically binds to SOD1 mRNA, inhibiting the production of toxic SOD1 protein, thereby improving biomarkers of ALS. The long-term efficacy and safety of tofersen require further validation, and the development of more optimized treatment protocols is essential. A series of studies and therapeutic developments related to SOD1 mutations have advanced the understanding of ALS pathophysiology and significantly contributed to treatment strategies for central nervous system disorders. This review focuses on an overview of SOD1 mutations and the development process of tofersen, aiming to deepen the understanding of advancements in ALS research and discuss future challenges and directions for ASO therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisSuperoxide Dismutase-1Oligonucleotides, AntisenseMutationHumansAnimalsOligonucleotides

Stichwörter der Autor:innen

amyotrophic lateral sclerosis (ALS)antisense oligonucleotide (ASO)central nervous system (CNS)superoxide dismutase 1 (SOD1)tofersen

Substanzen

Superoxide Dismutase-1Oligonucleotides, AntisenseSOD1 protein, humanOligonucleotides

Autor:innen und Institutionen

  • Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
  • The Friends of Garrett Cumming Research & Muscular Dystrophy Canada HM Toupin Neurological Sciences Research, Edmonton, AB T6G 2H7, Canada.

ORCID-Profile: Hidenori Moriyama, Toshifumi Yokota

Förderung

  • Friends of Garrett Cumming Research Fund
  • Muscular Dystrophy Canada
  • Canadian Institute of Health Research (CIHR)
  • Women and Children’s Health Research Institute (WCHRI)
  • HM Toupin Neurological Science Research Fund
  • U.S. Department of Defense
  • Heart and Stroke Foundation Canada
  • University of Alberta Faculty of Graduate and Postdoctoral Studies

Zitieren

APA

Moriyama, H., & Yokota, T. (2024). Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen. Genes. https://doi.org/10.3390/genes15101342

Vancouver

Moriyama H, Yokota T. Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen. Genes. 2024. doi:10.3390/genes15101342

BibTeX
@article{Moriyama2024,
  author = {Moriyama, Hidenori and Yokota, Toshifumi},
  title = {Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15101342}
}
Kostenlos starten →